Axial Spondyloarthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Therapy (Anti-Tumor Necrosis Factor (TNF) Therapy, Anti-Interleukin (IL) Therapy, Anti-Janus Kinase (JAK) Therapy), By Indication (Ankylosing Spondylitis v/s Non-radiographic Axial Spondyloarthritis Treatment), By End User (Hospitals & Clinics, Academic & Research Institutions, Others), By Company, and By Region
The global axial spondyloarthritis treatment market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors, including the rising incidence of axial spondyloarthritis and increasing public awareness of the disease, are propelling the growth of the market. Axial spondyloarthritis is a chronic inflammatory condition that impacts the axial skeleton. The person undergoes severe discomfort, stiffness in the back area, and fatigue because of it. The other factors supporting the market’s growth are the growing world population, increasing research activities, a surge in the number of patients, a large number of clinical trials, rising product innovation and development, significant investment in research and development, rising per capita health care expenditure, increasing prevalence of axial spondyloarthritis, growing number of mergers and acquisitions, and rising emphasis of several authorities on improving existing healthcare infrastructure.
A surge in Incidences of Axial Spondylarthritis
The increasing prevalence of axial spondylarthritis across the globe is bolstering the growth of the market. The cause of axial spondylarthritis is not known, but after several research, it is assumed that it is caused due to the exposure of genes to certain bacteria, viruses, or other triggers. Patients undergo serious discomforts, such as stiffness in the affected part and fatigue. Not only the elderly population but the younger generation are also prone to the disease. Therefore, these factors are bolstering the growth of the market globally. According to a cited study, in the U.S., about 2.7 million Americans or more are affected by axial spondyloarthritis (axSpA).
Increase in the Number of Approved Biosimilars
According to the World Health Organization (WHO), Biosimilars refer to a biotherapeutic product that is similar in terms of safety, quality, and efficacy to an already licensed original biotherapeutic product. Biosimilars are biological drugs that help in treating diseases such as axial spondylarthritis. They are very effective in patients and have replaced originator drugs due to their greater accessibility. In the past few years, there has been a surge in the number of approved biosimilars for the treatment of axial spondylarthritis, which is augmenting the growth of the market globally. For instance, in 2020 and 2021, the U.S. Food and Drug Administration approved three novel products, i.e., Xeljanz, Taltz, and Cosentyx, to treat individuals with axial spondyloarthritis.
Increasing R&D Activities
Rise in research and development (R&D) activities in the molecular and immunologic field are propelling the growth of the market. Owing to the increase in research activities, the advent of novel biologic agents such as tumor necrosis factor (TNF) inhibitors, IL-23, and interleukin (IL)-17 inhibitors are surging. For instance, in 2022, UCB, a global biopharmaceutical company, announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints. BE MOBILE 1 is the primary study to measure the effectiveness and safety of bimekizumab in adults suffering from active non-radiographic axial spondyloarthritis (nr-axSpA). Moreover, the rising investments in the research activities by the government are facilitating the growth of the market.
Market Segmentation
The global axial spondyloarthritis treatment market is segmented into therapy, indication, end user, and company. Based on therapy, the market is divided into anti-tumor necrosis factor (TNF) therapy, anti-interleukin (IL) therapy, and anti-Janus kinase (JAK) therapy. Based on indication, the market is divided into ankylosing spondylitis and non-radiographic axial spondyloarthritis treatment. Based on end-user, the market is divided into hospitals & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rise in R&D activities in the country.
Market Players
Novartis International, AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Pfizer, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., AbbVie Inc, Bristol-Myers Squibb Company, and FunPep Co., Ltd. are some of the leading companies operating in the market.
Report Scope:
In this report, global axial spondyloarthritis treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Axial Spondyloarthritis Treatment Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
A surge in Incidences of Axial Spondylarthritis
The increasing prevalence of axial spondylarthritis across the globe is bolstering the growth of the market. The cause of axial spondylarthritis is not known, but after several research, it is assumed that it is caused due to the exposure of genes to certain bacteria, viruses, or other triggers. Patients undergo serious discomforts, such as stiffness in the affected part and fatigue. Not only the elderly population but the younger generation are also prone to the disease. Therefore, these factors are bolstering the growth of the market globally. According to a cited study, in the U.S., about 2.7 million Americans or more are affected by axial spondyloarthritis (axSpA).
Increase in the Number of Approved Biosimilars
According to the World Health Organization (WHO), Biosimilars refer to a biotherapeutic product that is similar in terms of safety, quality, and efficacy to an already licensed original biotherapeutic product. Biosimilars are biological drugs that help in treating diseases such as axial spondylarthritis. They are very effective in patients and have replaced originator drugs due to their greater accessibility. In the past few years, there has been a surge in the number of approved biosimilars for the treatment of axial spondylarthritis, which is augmenting the growth of the market globally. For instance, in 2020 and 2021, the U.S. Food and Drug Administration approved three novel products, i.e., Xeljanz, Taltz, and Cosentyx, to treat individuals with axial spondyloarthritis.
Increasing R&D Activities
Rise in research and development (R&D) activities in the molecular and immunologic field are propelling the growth of the market. Owing to the increase in research activities, the advent of novel biologic agents such as tumor necrosis factor (TNF) inhibitors, IL-23, and interleukin (IL)-17 inhibitors are surging. For instance, in 2022, UCB, a global biopharmaceutical company, announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints. BE MOBILE 1 is the primary study to measure the effectiveness and safety of bimekizumab in adults suffering from active non-radiographic axial spondyloarthritis (nr-axSpA). Moreover, the rising investments in the research activities by the government are facilitating the growth of the market.
Market Segmentation
The global axial spondyloarthritis treatment market is segmented into therapy, indication, end user, and company. Based on therapy, the market is divided into anti-tumor necrosis factor (TNF) therapy, anti-interleukin (IL) therapy, and anti-Janus kinase (JAK) therapy. Based on indication, the market is divided into ankylosing spondylitis and non-radiographic axial spondyloarthritis treatment. Based on end-user, the market is divided into hospitals & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rise in R&D activities in the country.
Market Players
Novartis International, AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Pfizer, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., AbbVie Inc, Bristol-Myers Squibb Company, and FunPep Co., Ltd. are some of the leading companies operating in the market.
Report Scope:
In this report, global axial spondyloarthritis treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Axial Spondyloarthritis Treatment Market, By Therapy:
- Anti-Tumor Necrosis Factor (TNF) Therapy
- Anti-Interleukin (IL) Therapy
- Anti-Janus Kinase (JAK) Therapy
- Axial Spondyloarthritis Treatment Market, By Indication:
- Ankylosing Spondylitis
- Non-radiographic Axial Spondyloarthritis Treatment
- Axial Spondyloarthritis Treatment Market, By End User:
- Hospitals & Clinics
- Academic & Research Institutions
- Others
- Axial Spondyloarthritis Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in Global Axial Spondyloarthritis Treatment Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL AXIAL SPONDYLOARTHRITIS TREATMENT MARKET
5. VOICE OF CUSTOMER
6. CLINICAL TRIAL ANALYSIS
7. GLOBAL AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy (Anti-Tumor Necrosis Factor (TNF) Therapy, Anti-Interleukin (IL) Therapy, Anti-Janus Kinase (JAK) Therapy)
7.2.2. By Indication (Ankylosing Spondylitis v/s Non-radiographic Axial Spondyloarthritis Treatment)
7.2.3. By End User (Hospitals & Clinics, Academic & Research Institutions, Others)
7.2.4. By Region
7.2.5. By Company (2021)
7.3. Market Map
8. NORTH AMERICA AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy
8.2.2. By Indication
8.2.3. By End User
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Axial Spondyloarthritis Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy
8.3.1.2.2. By Indication
8.3.1.2.3. By End User
8.3.2. Canada Axial Spondyloarthritis Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy
8.3.2.2.2. By Indication
8.3.2.2.3. By End User
8.3.3. Mexico Axial Spondyloarthritis Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy
8.3.3.2.2. By Indication
8.3.3.2.3. By End User
9. EUROPE AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy
9.2.2. By Indication
9.2.3. By End User
9.2.4. By Country
9.3. Europe: Country Analysis
9.3.1. France Axial Spondyloarthritis Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy
9.3.1.2.2. By Indication
9.3.1.2.3. By End User
9.3.2. Germany Axial Spondyloarthritis Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy
9.3.2.2.2. By Indication
9.3.2.2.3. By End User
9.3.3. United Kingdom Axial Spondyloarthritis Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy
9.3.3.2.2. By Indication
9.3.3.2.3. By End User
9.3.4. Italy Axial Spondyloarthritis Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Therapy
9.3.4.2.2. By Indication
9.3.4.2.3. By End User
9.3.5. Spain Axial Spondyloarthritis Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Therapy
9.3.5.2.2. By Indication
9.3.5.2.3. By End User
10. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy
10.2.2. By Indication
10.2.3. By End User
10.2.4. By Country
10.3. Asia-Pacific: Country Analysis
10.3.1. China Axial Spondyloarthritis Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapy
10.3.1.2.2. By Indication
10.3.1.2.3. By End User
10.3.2. India Axial Spondyloarthritis Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapy
10.3.2.2.2. By Indication
10.3.2.2.3. By End User
10.3.3. Japan Axial Spondyloarthritis Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapy
10.3.3.2.2. By Indication
10.3.3.2.3. By End User
10.3.4. South Korea Axial Spondyloarthritis Treatment Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Therapy
10.3.4.2.2. By Indication
10.3.4.2.3. By End User
10.3.5. Australia Axial Spondyloarthritis Treatment Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Therapy
10.3.5.2.2. By Indication
10.3.5.2.3. By End User
11. SOUTH AMERICA AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Therapy
11.2.2. By Indication
11.2.3. By End User
11.2.4. By Country
11.3. South America: Country Analysis
11.3.1. Brazil Axial Spondyloarthritis Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Therapy
11.3.1.2.2. By Indication
11.3.1.2.3. By End User
11.3.2. Argentina Axial Spondyloarthritis Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Therapy
11.3.2.2.2. By Indication
11.3.2.2.3. By End User
11.3.3. Colombia Axial Spondyloarthritis Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Therapy
11.3.3.2.2. By Indication
11.3.3.2.3. By End User
12. MIDDLE EAST AND AFRICA AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Therapy
12.2.2. By Indication
12.2.3. By End User
12.2.4. By Country
12.3. MEA: Country Analysis
12.3.1. South Africa Axial Spondyloarthritis Treatment Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Therapy
12.3.1.2.2. By Indication
12.3.1.2.3. By End User
12.3.2. Saudi Arabia Axial Spondyloarthritis Treatment Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Therapy
12.3.2.2.2. By Indication
12.3.2.2.3. By End User
12.3.3. UAE Axial Spondyloarthritis Treatment Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Therapy
12.3.3.2.2. By Indication
12.3.3.2.3. By End User
13. MARKET DYNAMICS
13.1. Drivers
13.2. Challenges
14. MARKET TRENDS & DEVELOPMENTS
15. COMPETITIVE LANDSCAPE (INCLUSIVE SWOT ANALYSIS)
15.1. Novartis International, AG
15.2. Eli Lilly and Company
15.3. Johnson & Johnson
15.4. UCB S.A.
15.5. Pfizer, Inc.
15.6. Kyowa Kirin Co., Ltd.
15.7. Merck & Co., Inc.
15.8. AbbVie Inc
15.9. Bristol-Myers Squibb Company
15.10. FunPep Co., Ltd.
16. STRATEGIC RECOMMENDATIONS
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL AXIAL SPONDYLOARTHRITIS TREATMENT MARKET
5. VOICE OF CUSTOMER
6. CLINICAL TRIAL ANALYSIS
7. GLOBAL AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy (Anti-Tumor Necrosis Factor (TNF) Therapy, Anti-Interleukin (IL) Therapy, Anti-Janus Kinase (JAK) Therapy)
7.2.2. By Indication (Ankylosing Spondylitis v/s Non-radiographic Axial Spondyloarthritis Treatment)
7.2.3. By End User (Hospitals & Clinics, Academic & Research Institutions, Others)
7.2.4. By Region
7.2.5. By Company (2021)
7.3. Market Map
8. NORTH AMERICA AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy
8.2.2. By Indication
8.2.3. By End User
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Axial Spondyloarthritis Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy
8.3.1.2.2. By Indication
8.3.1.2.3. By End User
8.3.2. Canada Axial Spondyloarthritis Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy
8.3.2.2.2. By Indication
8.3.2.2.3. By End User
8.3.3. Mexico Axial Spondyloarthritis Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy
8.3.3.2.2. By Indication
8.3.3.2.3. By End User
9. EUROPE AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy
9.2.2. By Indication
9.2.3. By End User
9.2.4. By Country
9.3. Europe: Country Analysis
9.3.1. France Axial Spondyloarthritis Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy
9.3.1.2.2. By Indication
9.3.1.2.3. By End User
9.3.2. Germany Axial Spondyloarthritis Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy
9.3.2.2.2. By Indication
9.3.2.2.3. By End User
9.3.3. United Kingdom Axial Spondyloarthritis Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy
9.3.3.2.2. By Indication
9.3.3.2.3. By End User
9.3.4. Italy Axial Spondyloarthritis Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Therapy
9.3.4.2.2. By Indication
9.3.4.2.3. By End User
9.3.5. Spain Axial Spondyloarthritis Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Therapy
9.3.5.2.2. By Indication
9.3.5.2.3. By End User
10. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy
10.2.2. By Indication
10.2.3. By End User
10.2.4. By Country
10.3. Asia-Pacific: Country Analysis
10.3.1. China Axial Spondyloarthritis Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapy
10.3.1.2.2. By Indication
10.3.1.2.3. By End User
10.3.2. India Axial Spondyloarthritis Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapy
10.3.2.2.2. By Indication
10.3.2.2.3. By End User
10.3.3. Japan Axial Spondyloarthritis Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapy
10.3.3.2.2. By Indication
10.3.3.2.3. By End User
10.3.4. South Korea Axial Spondyloarthritis Treatment Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Therapy
10.3.4.2.2. By Indication
10.3.4.2.3. By End User
10.3.5. Australia Axial Spondyloarthritis Treatment Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Therapy
10.3.5.2.2. By Indication
10.3.5.2.3. By End User
11. SOUTH AMERICA AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Therapy
11.2.2. By Indication
11.2.3. By End User
11.2.4. By Country
11.3. South America: Country Analysis
11.3.1. Brazil Axial Spondyloarthritis Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Therapy
11.3.1.2.2. By Indication
11.3.1.2.3. By End User
11.3.2. Argentina Axial Spondyloarthritis Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Therapy
11.3.2.2.2. By Indication
11.3.2.2.3. By End User
11.3.3. Colombia Axial Spondyloarthritis Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Therapy
11.3.3.2.2. By Indication
11.3.3.2.3. By End User
12. MIDDLE EAST AND AFRICA AXIAL SPONDYLOARTHRITIS TREATMENT MARKET OUTLOOK
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Therapy
12.2.2. By Indication
12.2.3. By End User
12.2.4. By Country
12.3. MEA: Country Analysis
12.3.1. South Africa Axial Spondyloarthritis Treatment Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Therapy
12.3.1.2.2. By Indication
12.3.1.2.3. By End User
12.3.2. Saudi Arabia Axial Spondyloarthritis Treatment Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Therapy
12.3.2.2.2. By Indication
12.3.2.2.3. By End User
12.3.3. UAE Axial Spondyloarthritis Treatment Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Therapy
12.3.3.2.2. By Indication
12.3.3.2.3. By End User
13. MARKET DYNAMICS
13.1. Drivers
13.2. Challenges
14. MARKET TRENDS & DEVELOPMENTS
15. COMPETITIVE LANDSCAPE (INCLUSIVE SWOT ANALYSIS)
15.1. Novartis International, AG
15.2. Eli Lilly and Company
15.3. Johnson & Johnson
15.4. UCB S.A.
15.5. Pfizer, Inc.
15.6. Kyowa Kirin Co., Ltd.
15.7. Merck & Co., Inc.
15.8. AbbVie Inc
15.9. Bristol-Myers Squibb Company
15.10. FunPep Co., Ltd.
16. STRATEGIC RECOMMENDATIONS
